Welcome to our dedicated page for Genprex news (Ticker: GNPX), a resource for investors and traders seeking the latest updates and insights on Genprex stock.
Genprex, Inc. (NASDAQ: GNPX) generates a steady flow of news as a clinical-stage gene therapy company developing treatments for cancer and diabetes. Its updates frequently center on progress in lung cancer trials with Reqorsa Gene Therapy (quaratusugene ozeplasmid) and preclinical advances in its diabetes program, GPX-002.
Investors following GNPX news can expect coverage of clinical trial milestones, such as dose-escalation results, Phase 2 expansion plans, new trial site additions, and peer-reviewed publications from studies like the Acclaim-1 and Acclaim-3 trials in non-small cell and small cell lung cancer. Company releases also highlight regulatory designations, including FDA Fast Track and Orphan Drug status for Reqorsa-based programs.
Another major news theme is preclinical and translational data. Genprex and its collaborators report findings on Reqorsa’s activity in specific lung cancer subtypes, including ALK-EML4-positive NSCLC models, as well as animal data showing TUSC2 upregulation, apoptosis induction, and survival benefits in xenograft studies. For diabetes, news often covers GPX-002 proof-of-concept data in Type 1 and Type 2 diabetes mouse and non-human primate models, including effects on beta-cell function and glucose control.
Genprex also issues corporate and regulatory announcements, such as registered direct offerings, at-the-market programs, warrant-related financings, and patent developments around Reqorsa combinations with PD-1 and PD-L1 antibodies. These items provide context on the company’s capital strategy and intellectual property position.
For readers tracking GNPX, this news stream offers insight into how Genprex’s gene therapy platforms are advancing through research, clinical development, regulatory interactions, and financing activities over time.
Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data showing the Pdx1/MafA (PM, GPX-002) gene therapy reversed HFD-induced hyperglycemia in Type 2 diabetic mouse models with complete rescue by four weeks after intrapancreatic AAV-8 delivery. CMV and RIP promoter constructs improved ex-vivo glucose-stimulated insulin secretion to levels similar to regular-diet controls. Electron microscopy showed more mature insulin granules and transcriptomic analysis indicated β-cell maturation. The poster (ASGCT 2026, Abstract 2419) is scheduled for May 13, 2026; the team notes technical translatability to humans via endoscopic retrograde cholangiopancreatography.
Genprex (NASDAQ:GNPX) announced that a research collaborator's abstract reporting positive clinical biomarker data for Reqorsa® Gene Therapy (quaratusugene ozeplasmid) was selected for publication at the 2026 ASCO Annual Meeting, May 29–June 2, 2026 in Chicago.
The abstract (e15184) describes predictive biomarkers for progression‑free survival (PFS) in patients receiving Reqorsa, which the company says may help enrich lung cancer trials and predict patient response.
Genprex (NASDAQ: GNPX) signed a Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN biomarkers that may predict response to REQORSA (quaratusugene ozeplasmid) gene therapy for NSCLC and SCLC. Research aims to refine patient selection for Acclaim-1 and Acclaim-3 trials and optimize outcomes.
Acclaim-1 (REQORSA + Tagrisso) completed Phase 1 dose escalation with no dose-limiting toxicities and showed early efficacy, including three of 12 patients with prolonged PFS and one patient with a partial response maintained through ~42 months. Acclaim-3 (REQORSA + Tecentriq) moved to Phase 2 after a Phase 1 with no DLTs and one unconfirmed partial remission.
Genprex (NASDAQ: GNPX) collaborators presented positive preclinical data for Reqorsa (quaratusugene ozeplasmid) at AACR 2026 (April 17-22). Studies showed 79% tumor shrinkage with Quar Oze plus alectinib in an ALK+ sensitive model (p=0.0135) and synergistic tumor reduction and survival benefit in an alectinib-resistant model (p=0.0001).
Additional findings: TROP2 low/PTEN high associated with primary resistance; Quar Oze restored NK cell activity, producing complete tumor regression in preclinical cohorts (up to 67%). All data are preclinical.
Genprex (NASDAQ: GNPX) collaborators will present positive preclinical data for Reqorsa (quaratusugene ozeplasmid) at the AACR Annual Meeting, April 17-22, 2026.
Key findings: Quar Oze induced up to 79% tumor shrinkage in ALK+ models (p=0.0135), synergized with alectinib (p=0.0001), drove complete regressions in mice (67% Tusc2 KO, 33% WT), and identified TROP2 low/PTEN high as potential resistance biomarkers.
Genprex (NASDAQ: GNPX) announced that its executive leadership will attend BIO Europe Spring in Lisbon, Portugal, March 23-25, 2026. Attendees include Ryan Confer, President and CEO, and Thomas Gallagher, SVP of Intellectual Property and Licensing.
Genprex said executives will be available for one-on-one meetings to provide overviews of the company’s gene therapy programs for cancer and diabetes; meeting requests can be made via the conference portal or investors@genprex.com.
Genprex (NASDAQ:GNPX) announced that the Japanese Patent Office issued a favorable appeal decision to grant a patent for REQORSA in combination with PD-L1 antibodies, and the European Patent Office issued a decision to grant a patent for REQORSA with PD-1 antibodies.
Genprex maintains exclusive licenses and says these patents strengthen protection for therapeutic combinations, including the Acclaim-3 small cell lung cancer trial combining REQORSA with PD-L1 antibodies. The company already holds related U.S. and Korea patents, and other international grants and pendings.
Genprex (NASDAQ: GNPX) announced IP Australia issued a Notice of Acceptance on Feb 5, 2026, for a patent application claiming use of Reqorsa® gene therapy combined with PD-L1 antibodies to treat cancers.
The company notes related patents are already granted in the U.S. and Korea and says the patent, if granted, will strengthen exclusivity in Australia while it advances the Acclaim-3 clinical trial and opens an additional site at the University of Kentucky.
Genprex (NASDAQ: GNPX) provided a clinical update for its diabetes gene therapy program for GPX-002 on January 7, 2026, reporting preclinical progress and regulatory planning.
Key developments: preclinical proof-of-concept in Type 2 diabetes mouse and non-human primate models showing beta cell rejuvenation and normalized glucose; prior T1D models showed restored normal glucose and improved c-peptide/insulin metrics; manufacturing process transferred to CDMO partners; and a FDA meeting request submitted by end of 2025, with the meeting scheduled in Q1 2026 to discuss IND-enabling studies and next steps toward toxicology studies and cGMP clinical scale production.
Genprex (NASDAQ: GNPX) announced preliminary preclinical in vivo proof-of-concept data for GPX-002, a diabetes gene therapy, from Type 2 diabetic non-human primate (NHP) and mouse studies dated Jan 6, 2026. Key findings: one NHP treated via pancreatic duct infusion achieved normal glucose tolerance at seven months; a second NHP treated by direct pancreatic injection improved glucose tolerance at three months but did not normalize; T2D mice showed statistically significant glucose tolerance improvement at four weeks and restoration of normal glucose levels. Studies used an AAV vector carrying Pdx1 and MafA with an insulin promoter. Ongoing work includes toxicology and IND planning.